{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:22:48Z","timestamp":1785435768472,"version":"3.56.0"},"reference-count":64,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health of the Republic of Kazakhstan","award":["BR25293293 \u201cIntroduction of therapy of hematological tumors using the chimeric antigenic receptor technology CAR-T into practical healthcare\u201d"],"award-info":[{"award-number":["BR25293293 \u201cIntroduction of therapy of hematological tumors using the chimeric antigenic receptor technology CAR-T into practical healthcare\u201d"]}]},{"award":["BR25293293 \u201cIntroduction of therapy of hematological tumors using the chimeric antigenic receptor technology CAR-T into practical healthcare\u201d"],"award-info":[{"award-number":["BR25293293 \u201cIntroduction of therapy of hematological tumors using the chimeric antigenic receptor technology CAR-T into practical healthcare\u201d"]}],"id":[{"id":"https:\/\/ror.org\/022syee28","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Lentiviral vectors (LVs) are indispensable tools in cell and gene therapy. Rising demand has created a global shortage of LVs, driving the development of novel packaging approaches. We report a novel vector packaging approach using autonomously replicating cytoplasmic RNAs (replicons) to express packaging proteins. Yellow fever virus (YFV) was used as a source of replicons encoding the HIV-1 Gag\u2013Pol polyprotein together with reporter or selectable markers. YFV replicons were able to establish chronic infection in HEK293FT cells. Replicons expressing HIV-1 Gag\u2013Pol containing the wild-type HIV-1 protease caused strong cytotoxicity, which prevented the selection of polyclonal cell pools harboring the replicon. In contrast, a replicon carrying the T26S mutation in the HIV-1 protease gene showed no measurable cytotoxic effects, enabling the generation of stable replicon-containing cell pools. The replicon cell pools were established using antibiotic selection and maintained Gag-Pol expression for at least ten passages under selection pressure. Using these first-generation replicon cell pools as packaging cells, LV production required only transient transfection of a transfer vector, a Tat\/Rev plasmid, and an envelope plasmid. Yields reached ~106 TU\/mL prior to concentration and ~109 TU from multilayer cell stacks, which fall within the range typically reported for conventional transient transfection systems under similar culture conditions. The resulting vectors efficiently transduced target cells, and no replication-competent lentivirus (RCL) was detected using a two-phase RCL assay with p24 ELISA detection. This demonstrator platform utilizing replicon cell pools represents a novel approach for LV packaging.<\/jats:p>","DOI":"10.3390\/biology15110848","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:08:02Z","timestamp":1780535282000},"page":"848","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of Replicon Cell Pools Bearing a Flavivirus RNA Replicon as a Source of HIV-1 Gag-Pol for Lentiviral Vector Production"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2199-5756","authenticated-orcid":false,"given":"Aitolkyn","family":"Kydyrbayeva","sequence":"first","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-2387","authenticated-orcid":false,"given":"Viktoriya","family":"Keyer","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolganay","family":"Kulatay","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-9302","authenticated-orcid":false,"given":"Gulzat","family":"Zauatbayeva","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakytkali","family":"Ingirbay","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Zhumabekova","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Abeev","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7868-3396","authenticated-orcid":false,"given":"Gaziza","family":"Nigmatulla","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9382","authenticated-orcid":false,"given":"Alexandr V.","family":"Shustov","sequence":"additional","affiliation":[{"name":"National Center for Biotechnology, Korgalzhin hwy 13\/5, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e10258","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current Progress in CAR-T Cell Therapy for Hematological Malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, R.P., Vessillier, S., and Rafiq, Q.A. (2021). Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses, 13.","DOI":"10.3390\/v13081528"},{"key":"ref_5","unstructured":"D\u2019Costa, S. (2026, May 10). Transformative Advances in Viral Vector Manufacturing: Unlocking Commercial Scalability, Consistency, and Cost-Effectiveness. Available online: https:\/\/www.pharmasalmanac.com\/articles\/transformative-advances-in-viral-vector-manufacturing-unlocking-commercial-scalability-consistency-and-cost-effectiveness."},{"key":"ref_6","unstructured":"Langhauser, K. (2026, May 10). 2025 Cell and Gene Challenges: Scalability, Supply Chain and Manufacturing. Available online: https:\/\/www.cellgenetherapyreview.com\/3975-Featured-Articles\/617533-2025-cell-and-gene-challenges-Scalability-supply-chain-and-manufacturing."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.18609\/cgti.2022.216","article-title":"Viral vector manufacturing process: Addressing bottlenecks with innovative solutions","volume":"8","author":"Legmann","year":"2022","journal-title":"Cell Gene Ther. Insights"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2000017","DOI":"10.1002\/biot.202000017","article-title":"Progress and Perspectives in the Development of Lentiviral Vector Producer Cells","volume":"16","author":"Ferreira","year":"2021","journal-title":"Biotechnol. J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Perry, C., and Rayat, A.C.M.E. (2021). Lentiviral Vector Bioprocessing. Viruses, 13.","DOI":"10.3390\/v13020268"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107868","DOI":"10.1016\/j.bej.2020.107868","article-title":"Lentiviral vector bioprocess economics for cell and gene therapy commercialisation","volume":"167","author":"Comisel","year":"2021","journal-title":"Biochem. Eng. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41591-021-01650-w","article-title":"Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: The HGB-205 trial","volume":"28","author":"Magrin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.18609\/cgti.2022.022","article-title":"The EuLV\u00ae system, an inducible stable producer cell line for lentiviral vector production","volume":"8","author":"Xue","year":"2022","journal-title":"Cell Gene Ther. Insights"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vallet, T., and Vignuzzi, M. (2025). Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development. Viruses, 17.","DOI":"10.3390\/v17040566"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zauatbayeva, G., Kulatay, T., Ingirbay, B., Shakhmanova, Z., Keyer, V., Zaripov, M., Zhumabekova, M., and Shustov, A.V. (2025). Application of Pseudoinfectious Viruses in Transient Gene Expression in Mammalian Cells: Combining Efficient Expression with Regulatory Compliance. Biomolecules, 15.","DOI":"10.3390\/biom15020274"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Molina, E., Chocarro-Wrona, C., Mart\u00ednez-Moreno, D., Marchal, J.A., and Boulaiz, H. (2020). Large-scale production of lentiviral vectors: Current perspectives and challenges. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12111051"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27383","DOI":"10.1074\/jbc.M702028200","article-title":"Persistent and stable gene expression by a cytoplasmic RNA replicon based on a noncytopathic variant Sendai virus","volume":"282","author":"Nishimura","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2019.10.012","article-title":"A Sendai Virus-Based Cytoplasmic RNA Vector as a Novel Platform for Long-Term Expression of MicroRNAs","volume":"15","author":"Sano","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"RP105978","DOI":"10.7554\/eLife.105978","article-title":"Cap-independent co-expression of dsRNA-sensing and NF-\u03baB pathway inhibitors enables controllable self-amplifying RNA expression with reduced immunotoxicity","volume":"14","author":"Lim","year":"2025","journal-title":"eLife"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.gt.3300711","article-title":"Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes","volume":"5","author":"Saeki","year":"1998","journal-title":"Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/hum.2020.310","article-title":"Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy","volume":"32","author":"Mulia","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/bit.28387","article-title":"A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens","volume":"120","author":"Joubert","year":"2023","journal-title":"Biotechnol. Bioeng."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.ymthe.2024.06.019","article-title":"Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo","volume":"32","author":"Hick","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1128\/JVI.02921-15","article-title":"Low-Fidelity Polymerases of Alphaviruses Recombine at Higher Rates to Overproduce Defective Interfering Particles","volume":"90","author":"Poirier","year":"2015","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1073\/pnas.081077198","article-title":"Factors regulating template switch in vitro by viral RNA-dependent RNA polymerases: Implications for RNA-RNA recombination","volume":"98","author":"Kim","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101601","DOI":"10.1016\/j.omtm.2025.101601","article-title":"Risks of replication-competent retro\/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?","volume":"33","author":"Farley","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"pdb-prot095703","DOI":"10.1101\/pdb.prot095703","article-title":"Monitoring Lentivirus Vector Stocks for Replication-Competent Viruses","volume":"2018","author":"Gao","year":"2018","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"McGee, C.E., Tsetsarkin, K.A., Guy, B., Lang, J., Plante, K., Vanlandingham, D.L., and Higgs, S. (2011). Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023247"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(04)16800-1","article-title":"Arguments for live flavivirus vaccines","volume":"364","author":"Hombach","year":"2004","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1074\/jbc.M205636200","article-title":"Cell killing by HIV-1 protease","volume":"278","author":"Blanco","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108814","DOI":"10.1016\/j.bej.2023.108814","article-title":"Process for production of chimeric antigen receptor\u2013transducing lentivirus particles using infection with replicon particles containing self-replicating RNAs","volume":"191","author":"Syzdykova","year":"2023","journal-title":"Biochem. Eng. J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Keyer, V., Kydyrbayeva, A., Kulatay, T., Zauatbayeva, G., Bazhenov, D., Ingirbay, B., Shakhmanova, Z., Zhumabekova, M., Ospanova, M., and Shustov, A.V. (2025). Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production. Biomolecules, 15.","DOI":"10.3390\/biom15081166"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhurinov, M.Z., Miftakhova, A.F., Keyer, V., Shulgau, Z.T., Solodova, E.V., Kalykberdiyev, M.K., Abilmagzhanov, A.Z., Talgatov, E.T., Ait, S., and Shustov, A.V. (2023). Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked. Molecules, 28.","DOI":"10.3390\/molecules28166142"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1002\/bit.28794","article-title":"Non-industrial production of therapeutic lentiviral vectors: How to provide vectors to academic CAR-T","volume":"121","author":"Keyer","year":"2024","journal-title":"Biotechnol. Bioeng."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"pdb-rot095695","DOI":"10.1101\/pdb.prot095695","article-title":"Titration of Lentivirus Vectors","volume":"2018","author":"Gao","year":"2018","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1525-0016(03)00167-9","article-title":"Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations","volume":"8","author":"Escarpe","year":"2003","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/mt.2010.278","article-title":"Replication-competent lentivirus analysis of clinical grade vector products","volume":"19","author":"Cornetta","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1089\/hum.2005.16.1227","article-title":"Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection","volume":"16","author":"Sastry","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1128\/jvi.69.11.7180-7186.1995","article-title":"An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity","volume":"69","author":"Konvalinka","year":"1995","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"ref_45","first-page":"92","article-title":"Global manufacturing of CAR T cell therapy","volume":"31","author":"Levine","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bit.21467","article-title":"Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification","volume":"98","author":"Segura","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2019.11.011","article-title":"Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media","volume":"17","author":"Bauler","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jgm.1370","article-title":"Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures","volume":"11","author":"Ansorge","year":"2009","journal-title":"J. Gene Med."},{"key":"ref_49","unstructured":"Patel, S., Fong, E., and George, H. (2026, May 10). Bioreactor Process Development and Scale-Up for Transient Transfection-Based Lentivirus Manufacturing in Suspension Cell Culture. Available online: https:\/\/www.merckmillipore.com\/BI\/en\/technical-documents\/technical-article\/pharmaceutical-and-biopharmaceutical-manufacturing\/viral-vector-upstream-processing\/lentivirus-manufacturing-bioprocess-development-scale-up."},{"key":"ref_50","unstructured":"Cai, Y., Jeffers, S., and Snyder, R. (2026, May 10). Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing. Available online: https:\/\/www.pharmasalmanac.com\/articles\/transient-transfection-at-a-large-scale-for-flexibility-in-clinical-and-commercial-vector-manufacturing."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2020.08.010","article-title":"Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor","volume":"19","author":"Powers","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101209","DOI":"10.1016\/j.omtm.2024.101209","article-title":"Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor","volume":"32","author":"Stibbs","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1073\/pnas.90.17.8033","article-title":"Vesicular stomatitis virus G glycoprotein pseudotyping of retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells","volume":"90","author":"Burns","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-5793(90)80966-M","article-title":"Substrate specificity of the HIV-1 proteinase","volume":"268","author":"Konvalinka","year":"1990","journal-title":"FEBS Lett."},{"key":"ref_55","unstructured":"Munro, T. (2026, May 10). Keep Calm and Use Pools. Available online: https:\/\/themedicinemaker.com\/issues\/2021\/articles\/dec\/keep-calm-and-use-pools\/."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2021). Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines, 9.","DOI":"10.20944\/preprints202107.0261.v1"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_58","first-page":"555","article-title":"Replicon-based vectors of positive strand RNA viruses","volume":"2","author":"Khromykh","year":"2000","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/JVI.74.9.4394-4403.2000","article-title":"Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors","volume":"74","author":"Varnavski","year":"2000","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1038\/s41598-018-23593-y","article-title":"LentiPro26: Novel stable cell lines for constitutive lentiviral vector production","volume":"8","author":"Rodrigues","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_61","unstructured":"VIVEbiotech (2026, May 22). VIVEbiotech Expands Lentiviral Vector Manufacturing Capabilities with EvoLVcell. Available online: https:\/\/www.vivebiotech.com\/en\/about-us\/news\/vivebiotech-expands-lentiviral-vector-manufacturing-capabilities-with-evolvcell\/."},{"key":"ref_62","unstructured":"Genezen (2026, May 22). Genezen Enters Licensing Agreement with CSL for the Cytegrity\u2122 Stable Lentivirus Production System, PRNewswire, Available online: https:\/\/www.prnewswire.com\/news-releases\/genezen-enters-licensing-agreement-with-csl-for-the-cytegrity-stable-lentivirus-production-system-302066863.html."},{"key":"ref_63","unstructured":"GEN (2026, May 22). Genezen Licenses CSL\u2019s Cytegrity Lentiviral Vector Production System, Genetic Engineering & Biotechnology News, Available online: https:\/\/www.genengnews.com\/topics\/bioprocessing\/genezen-licenses-csls-cytegrity-lentiviral-vector-production-system\/."},{"key":"ref_64","unstructured":"American Biological Safety Association (2026, May 05). Yellow Fever Virus (Vaccine Strain 17D). Available online: https:\/\/my.absa.org\/tiki-view_tracker_item.php?trackerId=18&itemId=27828&fullscreen=n."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/11\/848\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:21:52Z","timestamp":1780546912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/11\/848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["biology15110848"],"URL":"https:\/\/doi.org\/10.3390\/biology15110848","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}